Gene transfer as cancer therapy.

[1]  R. Grossman,et al.  Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Jaffee,et al.  Demonstration of a rational strategy for human prostate cancer gene therapy. , 1994, The Journal of urology.

[3]  E. Gilboa,et al.  The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. , 1994, Journal of immunology.

[4]  M. Moser,et al.  Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo , 1994, European journal of immunology.

[5]  L. Szekely,et al.  Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay , 1994, European journal of immunology.

[6]  J. Schlom,et al.  Immune response to a carcinoembryonic antigen polynucleotide vaccine. , 1994, Cancer research.

[7]  R T Prehn,et al.  Stimulatory effects of immune reactions upon the growths of untransplanted tumors. , 1994, Cancer research.

[8]  J. Mulé,et al.  Experimental and clinical studies of cytokine gene-modified tumor cells. , 1994, Human gene therapy.

[9]  J. Johnston,et al.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.

[10]  M. Sy,et al.  Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. , 1994, Science.

[11]  J. Berzofsky,et al.  Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. , 1994, Journal of immunology.

[12]  C. Meijer,et al.  Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas , 1994, The Journal of experimental medicine.

[13]  Simon C Watkins,et al.  Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. , 1994, Cancer research.

[14]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[15]  H L Robinson,et al.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Flavell,et al.  Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. , 1993, Journal of immunology.

[17]  M. Kay,et al.  Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Nabel,et al.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Kiessling,et al.  Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells , 1993, European journal of immunology.

[20]  M. Lotze,et al.  Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. , 1993, Journal of immunology.

[21]  G. Gaudernack,et al.  Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cells , 1993, European journal of immunology.

[22]  P. Srivastava,et al.  Heat shock protein 70-associated peptides elicit specific cancer immunity , 1993, The Journal of experimental medicine.

[23]  R. Derynck,et al.  Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. , 1993, Cancer research.

[24]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[25]  T Friedmann,et al.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[27]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[28]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. , 1993, International immunology.

[29]  D. Klatzmann,et al.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Jerome,et al.  Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. , 1993, Journal of immunology.

[31]  R. Steinman,et al.  Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo , 1993, The Journal of experimental medicine.

[32]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[33]  J. Berzofsky,et al.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. , 1993, Cancer research.

[34]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[35]  M. Colombo,et al.  Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma , 1993, The Journal of experimental medicine.

[36]  B. Rouse,et al.  Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells , 1993, Journal of virology.

[37]  K. Lukacs,et al.  Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors , 1993, The Journal of experimental medicine.

[38]  A. Levinson,et al.  Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.

[39]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[40]  G. Freeman,et al.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Rock,et al.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Uhr,et al.  Immunotoxins: magic bullets or misguided missiles? , 1993, Trends in pharmacological sciences.

[43]  G. Nabel,et al.  Immunotherapy of malignancy by in vivo gene transfer into tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Marshall,et al.  High efficiency gene transfer into primary human tumor explants without cell selection. , 1993, Cancer research.

[45]  R. Mulligan,et al.  The basic science of gene therapy. , 1993, Science.

[46]  A. McAdam,et al.  Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. , 1993, Cancer research.

[47]  Bin Wang,et al.  Gene inoculation generates immune responses against human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Brown,et al.  Integration of murine leukemia virus DNA depends on mitosis. , 1993, The EMBO journal.

[49]  H. Stauss,et al.  Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein , 1993, The Journal of experimental medicine.

[50]  R. Levy,et al.  Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma , 1993, Nature.

[51]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[52]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Blankenstein,et al.  Eosinophils infiltrating interleukin‐5 gene‐transfected tumors do not suppress tumor growth , 1993, European journal of immunology.

[54]  E. Gilboa,et al.  Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831] , 1993, The Journal of experimental medicine.

[55]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[56]  L. Smith,et al.  Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  V. Sondak,et al.  Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. , 1993, Cancer research.

[58]  E. Thorsby,et al.  T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restriction , 1993, European journal of immunology.

[59]  P. Pandolfi,et al.  Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. , 1993, Blood.

[60]  T. Blankenstein,et al.  Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. , 1993, Cancer research.

[61]  E. Gilboa,et al.  Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. , 1993, Journal of immunology.

[62]  K. Rock,et al.  Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. , 1993, Journal of immunology.

[63]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[64]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[65]  K. Rock,et al.  Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. , 1993, Journal of immunology.

[66]  T. Blankenstein,et al.  Macrophage colony‐stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression , 1993, European journal of immunology.

[67]  P. Srivastava,et al.  Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. , 1993, Advances in cancer research.

[68]  M. Tykocinski,et al.  Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. , 1993, Science.

[69]  R. Germain,et al.  The biochemistry and cell biology of antigen processing and presentation. , 1993, Annual review of immunology.

[70]  R. Webster,et al.  Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. , 1993, Vaccine.

[71]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[72]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[73]  G. Forni,et al.  Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. , 1992, Journal of immunology.

[74]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[75]  J. Banchereau,et al.  GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells , 1992, Nature.

[76]  E. Gilboa,et al.  Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. , 1992, Cancer research.

[77]  L. Liotta,et al.  Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. , 1992, Cancer research.

[78]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[79]  R. Elashoff,et al.  Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine , 1992, Annals of surgery.

[80]  M. Raffeld,et al.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer , 1992, The Journal of experimental medicine.

[81]  W. Paul,et al.  The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice , 1992, The Journal of experimental medicine.

[82]  B. Chain,et al.  Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[83]  K. Zatloukal,et al.  Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M. Emerman,et al.  Human immunodeficiency virus infection of cells arrested in the cell cycle. , 1992, The EMBO journal.

[85]  R. Steinman,et al.  Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes , 1992, The Journal of experimental medicine.

[86]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[87]  W. McBride,et al.  Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. , 1992, Cancer research.

[88]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[89]  M. Zöller,et al.  Reduced tumorigenicity of fibrosarcomas which constitutively generate il‐1α either spontaneously or following il‐1α gene transfer , 1992 .

[90]  A. Porgador,et al.  Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.

[91]  K. Zatloukal,et al.  High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[92]  K Zatloukal,et al.  Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[93]  E. Kieff,et al.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.

[94]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[95]  M. Tykocinski,et al.  Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[96]  O. Mandelboim,et al.  H-2K double transfectants of tumor cells as antimetastatic cellular vaccines in heterozygous recipients. Implications for the T cell repertoire. , 1992, Journal of immunology.

[97]  G. Kaplan,et al.  Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing , 1992, The Journal of experimental medicine.

[98]  S. Rosenberg,et al.  A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability , 1992, The Journal of experimental medicine.

[99]  T. Honjo,et al.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[100]  T. Friedmann,et al.  Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1 , 1992, Journal of virology.

[101]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[102]  B. Rouse,et al.  Liposomes as antigen delivery systems in viral immunity. , 1992, Seminars in immunology.

[103]  H. Ljunggren,et al.  Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells , 1992, The Journal of experimental medicine.

[104]  Wei Chen,et al.  T-cell immunity to the joining region of p210BCR-ABL protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[105]  B. Rouse,et al.  Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro , 1992, The Journal of experimental medicine.

[106]  P. Coulie,et al.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells , 1992, International journal of cancer.

[107]  L. Luzzatto.  Frontiers in medicine: Gene transfer and gene therapy , 1992 .

[108]  W. Chen.  T cell immunity to the joining region of p210^ protein. , 1992 .

[109]  M. Emerman,et al.  Erratum: Human immunodeficiency virus infection of cells arrested in the cell cycle. The EMBO Journal (1992)11(3053-3058) , 1992 .

[110]  M. Lotze.  T-cell growth factors and the treatment of patients with cancer. , 1992, Clinical immunology and immunopathology.

[111]  T. Boon.  Toward a genetic analysis of tumor rejection antigens. , 1992, Advances in cancer research.

[112]  R. Blaese,et al.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[113]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[114]  D. Housman,et al.  Targeted integration of adeno‐associated virus (AAV) into human chromosome 19. , 1991, The EMBO journal.

[115]  T. Blankenstein,et al.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection , 1991, The Journal of experimental medicine.

[116]  M. Malim,et al.  Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes , 1991, The Journal of experimental medicine.

[117]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[118]  H. Schild,et al.  Efficiency of peptides and lipopeptides for in vivo priming of virus‐specific cytotoxic T cells , 1991, European journal of immunology.

[119]  H. Oettgen.  Cytokines in clinical cancer therapy. , 1991, Current opinion in immunology.

[120]  J. Wilson,et al.  Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. , 1991, The Journal of biological chemistry.

[121]  B. Moss,et al.  Vaccinia virus: a tool for research and vaccine development , 1991, Science.

[122]  B. Rollins,et al.  Suppression of tumor formation in vivo by expression of the JE gene in malignant cells , 1991, Molecular and cellular biology.

[123]  R. Bast,et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.

[124]  T. Boon,et al.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice , 1991, The Journal of experimental medicine.

[125]  R. Gallo,et al.  Tumor antigen presentation by murine epidermal cells. , 1991, Journal of immunology.

[126]  S. Rosenberg,et al.  Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.

[127]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[128]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[129]  K. Tracey,et al.  Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[130]  H. Volk,et al.  Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer , 1991, The Journal of experimental medicine.

[131]  M. Colombo,et al.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo , 1991, The Journal of experimental medicine.

[132]  Wei Chen,et al.  T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. , 1991, Journal of immunology.

[133]  S. Rosenberg,et al.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes , 1991, The Journal of experimental medicine.

[134]  P. Frost,et al.  Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. , 1991, Cancer research.

[135]  O. Scott.  Tumor transplantation and tumor immunity: a personal view. , 1991, Cancer research.

[136]  J. Renauld,et al.  Autonomous growth and tumorigenicity induced by P40/interleukin 9 cDNA transfection of a mouse P40-dependent T cell line , 1991, The Journal of experimental medicine.

[137]  E. Unanue,et al.  Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells , 1991, Cell.

[138]  H. Schluesener,et al.  Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins , 1991, The Journal of experimental medicine.

[139]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[140]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[141]  L. Chen,et al.  Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[142]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[143]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[144]  G. Forni,et al.  Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. , 1990, Journal of immunology.

[145]  J. Bryan,et al.  An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[146]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[147]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[148]  P. Greenberg,et al.  The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. , 1990, Science.

[149]  K. Rock,et al.  Presentation of exogenous antigen with class I major histocompatibility complex molecules. , 1990, Science.

[150]  S. Kennel,et al.  Lipid composition is important for highly efficient target binding and retention of immunoliposomes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[151]  R. Steinman,et al.  Dendritic cells pulsed with protein antigens in vitro can prime antigen- specific, MHC-restricted T cells in situ [published erratum appears in J Exp Med 1990 Oct 1;172(4):1275] , 1990, The Journal of experimental medicine.

[152]  P. Chomez,et al.  Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide , 1990, The Journal of experimental medicine.

[153]  S. Ostrand-Rosenberg,et al.  Rejection of mouse sarcoma cells after transfection of MHC class II genes. , 1990, Journal of immunology.

[154]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.

[155]  S. Rosenberg,et al.  Antitumor activity of recombinant interleukin 6 in mice , 1990, The Journal of experimental medicine.

[156]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[157]  H. Koeppen,et al.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[158]  M. Bevan,et al.  Class I-restricted processing and presentation of exogenous cell- associated antigen in vivo , 1990, The Journal of experimental medicine.

[159]  T. Yokota,et al.  Cytokines: coordinators of immune and inflammatory responses. , 1990, Annual review of biochemistry.

[160]  K. Hui,et al.  Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. , 1989, Journal of immunology.

[161]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[162]  H. Rammensee,et al.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine , 1989, Nature.

[163]  R. Offringa,et al.  Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes , 1989, Cell.

[164]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[165]  S. Shu,et al.  Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. , 1989, Journal of immunology.

[166]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[167]  D. Metcalf,et al.  The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells , 1989, Nature.

[168]  B. Askonas,et al.  Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro , 1989, The Journal of experimental medicine.

[169]  P. Möller,et al.  Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. , 1989, Journal of immunology.

[170]  F. Momburg,et al.  Selective loss of beta 2-microglobulin mRNA in human colon carcinoma , 1989, The Journal of experimental medicine.

[171]  R. Steinman,et al.  Distinct features of dendritic cells and anti-Ig activated B cells as stimulators of the primary mixed leukocyte reaction , 1989, The Journal of experimental medicine.

[172]  L. Esserman,et al.  Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. , 1989, International reviews of immunology.

[173]  A. Townsend,et al.  Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.

[174]  S. Hakomori,et al.  Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. , 1989, Advances in cancer research.

[175]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[176]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[177]  E. Borrelli,et al.  Targeting of an inducible toxic phenotype in animal cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[178]  X. Breakefield,et al.  A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. , 1988, Science.

[179]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[180]  K. Berkner.  Development of adenovirus vectors for the expression of heterologous genes. , 1988, BioTechniques.

[181]  T. Gajewski,et al.  Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. , 1988, Journal of immunology.

[182]  W. Kast,et al.  Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. , 1988, Journal of immunology.

[183]  W. Linehan,et al.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  P. Chomez,et al.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[185]  M. Zöller,et al.  Interferon‐gamma treatment of B16 melanoma cells: Opposing effects for non‐adaptive and adaptive immune defense and its reflection by metastatic spread , 1988, International journal of cancer.

[186]  J. Rowley,et al.  Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[187]  S. Knight,et al.  Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies , 1987, The Journal of experimental medicine.

[188]  R. Steinman,et al.  Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells , 1987, The Journal of experimental medicine.

[189]  T. Itaya,et al.  Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld). , 1987, Cancer research.

[190]  B. Aggarwal,et al.  Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. , 1987, Journal of immunology.

[191]  C. Janeway,et al.  The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. , 1987, Journal of immunology.

[192]  J. Nevins,et al.  Developmental control of a promoter-specific factor that is also regulated by the E1A gene product , 1987, Cell.

[193]  K. Tanaka,et al.  Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[194]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[195]  K. Nomoto,et al.  Synergistic defense system by cooperative natural effectors against metastasis of B16 melanoma cells in H-2-associated control: different behavior of H-2+ and H-2- cells in metastatic processes. , 1986, Journal of immunology.

[196]  P. Greenberg,et al.  Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long- term as functional memory T cells , 1986, The Journal of experimental medicine.

[197]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[198]  H. Grey,et al.  Antigen presentation by splenic B cells: resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses. , 1985, Journal of immunology.

[199]  C. Doré,et al.  Influence of dendritic cells on tumor growth. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[200]  P. Greenberg,et al.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells , 1985, The Journal of experimental medicine.

[201]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[202]  G. Forni,et al.  Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. , 1985, Journal of immunology.

[203]  R. North.  Down-regulation of the antitumor immune response. , 1985, Advances in cancer research.

[204]  J. Tratschin,et al.  A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase , 1984, Molecular and cellular biology.

[205]  S. Rosenberg,et al.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.

[206]  L. Huang,et al.  pH-sensitive liposomes: acid-induced liposome fusion. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[207]  F. Grosveld,et al.  Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation , 1984, Nature.

[208]  H. Grey,et al.  B cells as antigen-presenting cells: the requirement for B cell activation. , 1983, Journal of immunology.

[209]  T. Boon,et al.  Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis , 1983, The Journal of experimental medicine.

[210]  D. Baltimore,et al.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus , 1983, Cell.

[211]  J. Bishop.  Cellular oncogenes and retroviruses. , 1983, Annual review of biochemistry.

[212]  T. Boon,et al.  Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[213]  R. Wiltrout,et al.  Role of NK cells in the control of metastatic spread and growth of tumor cells in mice , 1982, International journal of cancer.

[214]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[215]  H. Macdonald,et al.  Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors , 1981, The Journal of experimental medicine.

[216]  N. Jones,et al.  Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. , 1980, Cold Spring Harbor symposia on quantitative biology.

[217]  N. Jones,et al.  Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells , 1979, Cell.

[218]  T. Boon,et al.  Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[219]  H. Morse.  Origins of inbred mice. , 1978 .

[220]  G. Snell.  CONGENIC RESISTANT STRAINS OF MICE , 1978 .

[221]  H. Hewitt.  The choice of animal tumors for experimental studies of cancer therapy. , 1978, Advances in cancer research.

[222]  H. Hewitt,et al.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. , 1976, British Journal of Cancer.

[223]  J. Klein.  Biology of the Mouse Histocompatibility-2 Complex , 1975, Springer Berlin Heidelberg.

[224]  M. Kripke,et al.  Antigenicity of murine skin tumors induced by ultraviolet light. , 1974, Journal of the National Cancer Institute.

[225]  J. Jami,et al.  Expression of tumor-specific antigens in mouse somatic cell hybrids. , 1973, Cancer research.

[226]  M. A. Basombrío.  Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. , 1970, Cancer research.

[227]  J. Watkins,et al.  Immunization of Mice against Ehrlich Ascites Tumour using a Hamster/Ehrlich Ascites Tumour Hybrid Cell Line , 1969, Nature.

[228]  C. Barker,et al.  THE ROLE OF REGIONAL LYMPHATICS IN THE SKIN HOMOGRAFT RESPONSE , 1967, Transplantation.

[229]  S. Strober,et al.  THE ROLE OF LYMPHOCYTES IN THE SENSITIZATION OF RATS TO RENAL HOMOGRAFTS , 1965, The Journal of experimental medicine.

[230]  F. Rapp,et al.  IMMUNITY IN HAMSTERS TO CELLS TRANSFORMED IN VITRO AND IN VIVO BY SV40. TESTS FOR ANTIGENIC RELATIONSHIP AMONG THE PAPOVAVIRUSES. , 1963, Journal of immunology.

[231]  G. Klein,et al.  Resistance of polyoma virus immunized mice to transplantation of established polyoma tumors , 1961 .

[232]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[233]  L. Révész.  Detection of Antigenic Differences in Isologous Host-Tumor Systems by Pretreatment with Heavily Irradiated Tumor Cells , 1960 .

[234]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[235]  Baldwin Rw.  Immunity to Methylcholanthrene-Induced Tumours in Inbred Rats Following Atrophy and Regression of the Implanted Tumours , 1955 .

[236]  Foley Ej.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953 .

[237]  E. J. Foley.  Attempts to induce immunity against mammary adenocarcinoma in inbred mice. , 1953, Cancer research.

[238]  L. Gross.  Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line , 1943 .

[239]  P. Gorer.  The antigenic basis of tumour transplantation , 1938 .

[240]  P. Rous,et al.  AN EXPERIMENTAL COMPARISON OF TRANSPLANTED TUMOR AND A TRANSPLANTED NORMAL TISSUE CAPABLE OF GROWTH , 1910, The Journal of experimental medicine.